Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cerebral Toxoplasmosis.

Avindra Nath1, Anthony P. Sinai

  • 1*Department of Neurology, Johns Hopkins University Medical School, 600 North Wolfe Street, Baltimore, MD 21287, USA. anath1@jhmi.edu

Current Treatment Options in Neurology
|January 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurological Manifestations in Adult Survivors of Ebola Virus Disease.

JAMA neurology·2026
Same author

The next phase in Long COVID research: addressing the ethical challenges in trials of disease-modifying treatments.

EClinicalMedicine·2026
Same author

Functional Activity of TDP-43: A Direct Biomarker for ALS.

medRxiv : the preprint server for health sciences·2026
Same author

Designing studies for post-treatment Lyme disease and other infection-associated chronic illnesses.

Brain : a journal of neurology·2026
Same author

Genetic mechanisms underlying host susceptibility to central nervous system viral infections.

Current opinion in infectious diseases·2026
Same author

Downregulation of miRNAs Accompanies Increased HERV-K (HML-2) Expression in Amyotrophic Lateral Sclerosis.

Molecular neurobiology·2026
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Treating cerebral toxoplasmosis, especially in AIDS patients, requires effective drug combinations like sulfadiazine and pyrimethamine. New therapies are needed due to drug resistance and side effects, with folinic acid preventing bone marrow suppression.

Area of Science:

  • Infectious Diseases
  • Neurology
  • Pharmacology

Background:

  • Cerebral toxoplasmosis treatment options are limited, with pyrimethamine and sulfonamides being the primary combination.
  • Clindamycin serves as an alternative, while spiramycin is less effective for CNS infections but useful during pregnancy.
  • Long-term maintenance therapy is crucial for patients with AIDS, highlighting the need for diverse antibiotic choices to combat resistance and side effects.

Purpose of the Study:

  • To review current treatment strategies for cerebral toxoplasmosis.
  • To emphasize the need for expanded therapeutic options.
  • To outline diagnostic and monitoring approaches for cerebral toxoplasmosis.

Main Methods:

  • Review of existing literature on cerebral toxoplasmosis pharmacotherapy.

Related Experiment Videos

  • Analysis of drug efficacy, resistance patterns, and side effect profiles.
  • Discussion of empirical treatment initiation and diagnostic criteria.

    • Main Results:

    • Sulfadiazine and pyrimethamine combination therapy is the current standard of care.
    • Folinic acid is recommended to mitigate pyrimethamine-induced bone marrow suppression.
    • Neuroimaging is essential for treatment efficacy assessment, with lifelong therapy indicated for patients with low CD4 counts.

    Conclusions:

    • Current drug choices for cerebral toxoplasmosis are limited, necessitating the development of new therapeutic agents.
    • Prompt diagnosis and appropriate management, including lifelong therapy for some patients, are critical.
    • Advances in understanding Toxoplasma biology promise novel treatment strategies in the future.